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Eltrombopag has been used in ITP and found its use in AA armamentarium recently.
We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January
2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive
therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to
Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI
issues were notable.
We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Abbreviations
AA:
Aplastic anemia
allo-HSCT: Allogeneic hematopoietic stem cell transplantation
ATG:
Anti-thymocyte globulin
CTCAE: Criteria for Adverse Events
CYA:
cyclosporine A
ELT:
Eltrombopag
GI:
Gastrointestinal disturbance
HSCs:
Hematopoietic stem cells
ITP:
Immune thrombocytopenia
SAA:
Severe aplastic anemia
1. Introduction
Aplastic anemia (AA) is a form of bone marrow failure caused by Tcell mediated destruction of hematopoietic stem cells (HSCs) and is lifethreatening if untreated [1]. Allogeneic hematopoietic stem cell trans
plantation (allo-HSCT) is potentially curative, however, for those not
eligible, the standard therapy consists of immunosuppression with horse
anti-thymocyte globulin (ATG) and cyclosporine A (CYA) [2]. About
70% of patients do respond, but survival with good marrow function
without relapse is in the order of only 30–40% [3]. Treatment options

are unsatisfactory for patient’s refractory to or relapsing after first-line
treatment especially when they are transplant ineligible. Furthermore,
the intensive immunosuppressive ATG-CYA combination cannot be
applied in a proportion of AA patients due to severe infections [4].
Immune thrombocytopenia (ITP) is an autoimmune disorder char
acterized by an abnormally low number of circulating platelets, <100 ×
103/µl which promotes bleeding tendency. Intracranial hemorrhage is a
life-threatening complication and occurs especially when the platelet
count drops below 10 × 103/µl [5]. The incidence of primary ITP in
adults is 3.3/100,000/year. ITP incidence is multimodal and exhibits
three peaks in children, young adults, women aged 30–40 years, and the
elderly. The prevalence in adults is 9.5/100,000. The exact mechanism
that leads to ITP is poorly understood, although it is well known that
antiplatelet autoantibodies play a key role. These appear because of an
altered T-cell response, in which the splenic T follicular helper cells are
involved as inducers of the proliferation and differentiation of autor
eactive B-cells [6]. These produce antiplatelet autoantibodies, predom
inantly of the immunoglobulin (Ig) G isotype, which can react with a
series of platelet receptors, mainly glycoprotein (GP) IIb/IIIa and GPI
b/IX, but also GPV, GPIa/IIa, or GPIV. These auto epitopes [7] induce
cell destruction. These platelets experience splenic sequestration and
subsequent phagocytosis by mononuclear macrophages, which react
with the cell-complexed autoantibodies. Macrophages still play an
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additional harmful role in ITP since they behave as the main
antigen-presenting cell [8]. CD8+T-cells also contribute to thrombocy
topenia by increasing platelet apoptosis [9]. Recently, the Ash
well–Morell receptor (AMR), which is an asialoglycoprotein counter
receptor predominantly expressed in hepatocytes, has also been shown
to play an important role in anti-GPIbα antibody-mediated platelet
clearance. Consequently, the circulating half-life of platelets is markedly
reduced. In addition, bone marrow megakaryocytes are unable to pro
duce platelets normally, which further increases thrombocytopenia. The
likely reason is that on one hand, there are autoimmune responses
against megakaryocytes while on the other hand, the circulating
thrombopoietin (TPO), which is the main growth factor of megakaryo
cytes, does not increase to a level high enough to cause sufficient
stimulation [10].
Currently, ITP is categorized according to duration, as newly diag
nosed (<3 months), persistent (3–12 months), or chronic (> 12 months)
[11].
ELT is a synthetic, low molecular weight thrombopoietin receptor
agonist (TPO-RA). It has been used in ITP and recently found its use in
the AA therapy armamentarium. Unlike native TPO, which binds to the
extracellular domain of thrombopoietin receptor (TPO-R), ELT interacts
with the transmembrane domain of the latter. Therefore, the Janus ki
nases (JAKs), signal transducer, and activator of transcription proteins
(STAT) i.e., JAK/STAT signaling pathway stimulate mega
karyocytopoiesis, while not detecting autoantibody generation [12].
ELT does not influence agonist-induced platelet aggregation or activa
tion. With good oral bioavailability, circulating peaks are found 2–6 h
after oral administration. Metabolism takes place in the liver via cyto
chrome P450 isoenzymes with a half-life of 21–32 h [13].
In contrast to previous failed attempts to stimulate the HSC
compartment by diverse growth factors such as G-CSF, GM-CSF, or EPO,
ELT induced trilinear hematopoietic responses in refractory AA patients
[14]. Mechanistically, ELT binds to the TPO receptor c-MPL expressed
on HSCs and leads to their proliferation and expansion [15, 16]. Addi
tional immunomodulatory effects may be involved. Results of a phase II
trial examining ELT monotherapy in refractory AA patients showing a
40% response rate led to the approval of ELT as monotherapy in
relapsed-refractory AA in the USA and Europe. Recently, the increased
response rate to ELT in combination with standard ATG-CYA immuno
suppression as compared to historical controls has been reported by the
NIH group [17] and the use of ELT in the first-line setting is currently
underway.
Our work is the first such effort in the region, where the role of ELT in
both benign hematological disorders is studied retrospectively. We hy
pothesize that the role of ELT in our population would be reflective of
the studies performed in the EXTEND trial [18] for ITP patients and in
concordance with previous studies in severe AA [19].

Immune thrombocytopenia was defined as having platelets, <100 ×
103/µl in the absence of any underlying disorder. Included patients had
at least a 3-month history of ITP (Persistent/Chronic); included both
primary and secondary (associated with autoimmune diseases, malig
nancy, infections, and others cause) ITP; received at least one previous
treatment for ITP and had a platelet count of less than 30,000 per cubic
millimeter at enrollment. Patients who were receiving maintenance
immunosuppressive regimens, primarily glucocorticoids, were eligible if
the dose had been stable for at least 1 month. The dose had to remain
unchanged throughout the study. Patients were excluded if they had
hemoglobin levels of less than 9 gs per deciliter; had congestive heart
failure; had a history of arrhythmias; had a history of thrombosis or
myocardial infarction within 3 months and/or were women who were
nursing or pregnant.
Following data was extracted from medical records after depart
mental and ethical approval: patient age, sex, severe aplastic anemia
(SAA), ITP, presenting complete blood counts, history of bleeding, and
splenectomy status in ITP patients. Following post-intervention vari
ables were extracted in AA: 1) platelet response; 2) erythroid lineage
response; 3) leucocyte response; and 4) treatment failure. While postintervention variables extracted in ITP were as follows: 1) good
response; 2) partial response and 3) no response. Common Terminology
Criteria for Adverse Events (CTCAE) version 5.0 was used to assess the
toxicity profile. It included hepatotoxicity, thromboembolic event,
portal vein thrombosis, nasopharyngitis, upper respiratory tract infec
tion, nausea, vomiting, diarrhea, and skin rash. ELT treatment was
initiated at a minimum daily dose of 50 mg and a maximum of 75 mg.
This was adjusted as per response during a total duration of at least 6
weeks. Lower doses compared to the western population were used
based on the population pharmacokinetics of ELT in East Asia [20, 21].
Response to the treatment in each group was assessed according to
National Institutes of Health (NIH) criteria, which is as follows.
2.1. Response for aplastic anemia
A platelet response was defined by a platelet count increase of 20 ×
109/L above baseline or stable platelet counts with no transfusions for at
least 8 weeks. An erythroid lineage response was defined as a hemo
globin increase of >1.5 g/dL or a reduction of >4 units of transfused
erythrocytes for 8 consecutive weeks. A leukocyte response was defined
as an absolute neutrophil increase of 100% or an absolute neutrophil
count increase of >0.5 × 109/L. Not achieving at least one of these
criteria during ELT treatment was considered a treatment failure.
2.2. Response for immune thrombocytopenia
Platelet count of more than 50 × 109/L was considered a good
response; partial response when the platelet count ranged between 30
and 50 × 109/L with at least a 2-fold increase in the initial platelet
count; and no response when the platelet count was 30 × 109/L and less.
No missing data on scale variables were observed. Median and
Interquartile range (IQR) was computed for continuous variables like
age, length of hospital stays, and blood parameters. Frequencies and
percentages were calculated for categorical variables like gender,
bleeding, and toxicity. The data was stratified accordingly i.e., SAA and
ITP, baseline, clinical characteristics, and treatment response was
compared using the Chi-Square test. In addition, a comparative analysis
of response between ELT versus non-ELT (standard treatment) group
was also performed. One-way ANOVA test was used to compare the preand post-treatment quantitative data. A p-value less than or equal to
0.05 was considered significant. The data were analyzed using Stata
version-15.

2. Methods
This retrospective chart review was conducted using electronic
medical records (EMR) for 60 male and female patients who were
treated with ELT for Severe Aplastic anemia and Immune thrombocy
topenia from January 2015 to January 2021 at a tertiary care hospital in
Karachi, Pakistan.
Severe Aplastic anemia was defined as having a hypocellular bone
marrow when two of three blood counts were met (absolute neutrophil
count <500/μL, absolute reticulocyte count <60,000/μL, platelet count
<20,000/μL). Included patients were refractory to at least one course of
immunosuppressive therapy, initiated at least in the last 6 months, and
were not candidates for stem cell transplant. Patients were excluded if
they had a diagnosis of Fanconi anemia on peripheral chromosomal
breakage analysis; MDS (ruled out on morphology and cytogenetics);
and/or diagnosed with paroxysmal nocturnal hemoglobinuria based on
the absence of CD 55 and CD 59 by gel card method. Women who were
nursing or pregnant were also excluded from the study.

3. Results
From January 2015 to January 2021, 61 patients including 32 Severe
2
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Aplastic Anemia (SAA) and 29 Immune Thrombocytopenia (ITP)
received ELT. The baseline characteristics of patients are presented in
Table 1.
The median (IQR) age of AA patients was 22.5 (16–34.5) years and
49 (38–57) years of ITP patients. Most of the AA patients were female 20
(62.5%), unlike the ITP patients who were mostly males, 19 (65.5%).
World Health Organization (W.H.O.) bleeding scale was used to grade
bleeding. At presentation 12 (38.7%) AA patients had grade III bleeding
and 13 (44.8%) ITP patients had grade II bleeding.
The toxicity profile of Immune Thrombocytopenia and Aplastic
Anemia patients are presented in Table 2. Hepatotoxicity and GI issues
were notable in both groups.
Response to ELT was classified into two groups for both AA and ITP.
The response of AA patients was categorized as platelet, erythroid
lineage, and leucocyte response respectively, which when all present
considered a complete response. In this population, platelet response
was seen in 29 (90.6%), erythroid lineage in 27 (84.4%), and leucocyte
response in 21 (65.6%) patients respectively (Fig. 1). A complete
response to ELT was seen in 17 (53.1%) AA patients (p = 0.001). There
was only 1 (3.1%) patient who failed treatment in the AA group (p =
0.692).
The response of ITP patients to ELT was classified as a ‘no’, ‘partial’,
and ‘good response’ respectively. In this group 25 (86.2%, p = 0.033)
ITP patients showed good response to the ELT (Fig. 2).
Analysis on the outcomes of AA and ITP patients who received ELT
compared with those who received standard (non-ELT) treatment was
also performed. Both treatment groups had an equivalent number of
patients (61 vs. 60).
ELT group showed significant improvement in clinical characteristics
compared with the non-ELT group. Median hemoglobin (g/dl) pre- vs.
post-treatment in AA patients who received ELT was 7.6 vs. 11.1 g/dl
while in the non-ELT group was 7.5 vs. 9.2 g/dl. Likewise, the median
white blood cell count in AA who received ELT pre- vs. post-treatment
was (1.4 vs. 6.9) x 109/L, while in the non-ELT group was (3.0 vs. 3.5)
x 109/L. Similarly, platelets count also showed an increase in both
groups but significantly in the ELT group. The median platelet counts in
AA and ITP patients who received ELT pre- vs. post-treatment were (9 vs.
70) x 109/L and (6 vs. 166) x 109/L respectively while (12 vs. 19) x 109/
L and (12 vs. 128) x 109/L in the non-ELT group. Similarly 17 (53.1%)
AA and 25 (86.2%) ITP patients in ELT group gave complete/good
response to treatment, while four (13.3%) AA and 23 (76.7%) ITP pa
tients in non-ELT group gave complete/good response to treatment,
which was significant (Table 3).

Table 2
Patient’s toxicity profile received ELT in immune thrombocytopenia and ac
quired idiopathic aplastic anemia (n = 61).
Characteristics
Hepatotoxicity
Grade 1/2
Grade 3/4
Thromboembolic event
Grade 1/2
Grade 3/4
UTI
Grade 1/2
Grade 3/4
Gastrointestinal
Grade 1/2
Grade 3/4
Rash
Grade 1/2
Grade 3/4

ELT is approved by both, the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) as a single agent in
severe AA patients who show an inadequate response to initial immu
nosuppression. FDA has also approved ELT as a component of triple IST

Table 1
Patients’ baseline characteristics received ELT in immune thrombocytopenia
and acquired idiopathic aplastic anemia (n = 61).
Disease n (%)
IAA (n = 32)

ITP (n = 29)

Median Age (years)
Gender
Male
Female
WHO bleeding scale
None
Grade I
Grade II
Grade III
Grade IV

22.5 (16–34.5)

49 (38–57)

<0.001

12 (37.5%)
20 (62.5%)

19 (65.5%)
10 (34.5%)

0.029

15 (48.4%)
2 (6.5%)
1 (3.2%)
12 (38.7%)
1 (3.2%)

13 (44.8%)
0 (0.0%)
13 (44.8%)
2 (6.9%)
1 (3.5%)

0.033

ITP (n = 29)

p-value

4 (12.9%)
3 (9.7%)

6 (20.7%)
1 (3.4%)

0.046

0 (0.0%)
1 (3.2%)

1 (3.4%)
1 (3.4%)

0.568

0 (0.0%)
7 (21.9%)

0 (0.0%)
1 (3.4%)

0.033

4 (12.5%)
10 (31.3%)

0 (0.0%)
1 (3.4%)

0.008

0 (0.0%)
5 (15.6%)

0 (0.0%)
0 (0.0%)

0.260

in treatment-naïve AA patients.
There has been no consensus yet about the most effective dose of ELT
in either AA or ITP. Individuals of East or Southeast Asian ancestry have
known population pharmacokinetic dynamics [22] and so are recom
mended to use lower doses(75 mg) of ELT compared to its normal dose
of 150 mg. The usual starting dosage at our center is 50 mg, increased to
75 mg at maximum.
Two important considerations with ELT are the cost and long-term
compliance to medications. In Pakistan, the government has taken
some initiatives along with pharmaceutical companies to provide ELT at
subsidized rates for the indication of ITP. However, financial issues in
third-world countries remain a significant hindrance to its use.
Previous medical literature has shown promising results with ELT in
different populations spanning different parts of the globe.
A prospective phase 1, 2 study on 92 patients by Danielle et al. found
that the addition of ELT to immunosuppressive therapy was associated
with markedly higher rates of hematologic response among patients
with severe aplastic anemia than in a historical cohort [23].
A phase 2 study by Matthew J et al. involving patients with aplastic
anemia that were refractory to immunosuppression was performed to
determine the response of ELT on blood counts. Eleven of 25 patients
(44%) had a hematologic response in at least one lineage at 12 weeks,
with minimal toxic effects [24].
In previous studies, ELT has been considered generally safe, although
skin reactions or elevation of hepatic transaminases have been noted
[23].
Common adverse events (≥20%) include nausea, fatigue, cough,
diarrhea, and headache while mild to moderate increase in indirect
bilirubin is a common finding, however without any clinically signifi
cant consequence to the patient [25]. It is notable, however, that the
effects of long-term use of ELT in AA have not been thoroughly evalu
ated. This includes the risk of clonal evolution.
In relevance to ITP, the ELT extended Dose study (EXTEND), in
which patients were followed for 3 years, the median daily dose was
approximately 50 mg in ITP patients [26]. Polyvalent cations such as
iron, calcium, aluminum, magnesium, selenium, and zinc are known to
reduce the absorption of ELT.
Xiaofan et al. in phase III, randomized, placebo-controlled study
assessed the long-term efficacy and safety of ELT use in chronic immune
thrombocytopenia (ITP) among the Chinese population. 32% of patients
achieved platelet counts ≥50 × 109/L in more than 75% of platelet
count assessments overall. The results further established a sustainable
long-term efficacy and tolerability of ELT in these patients [27].
Raymond et al. in the open-label EXTEND study evaluated the longterm safety and efficacy of ELT in adults with ITP who had completed a
previous ELT study. Among 302 enrolled patients who were followed for

4. Discussion

Characteristics

Disease n (%)
IAA (n = 32)

p-value
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Fig. 1. Treatment response to ELT in acquired idiopathic aplastic anemia.

Fig. 2. Treatment response to ELT in immune thrombocytopenia.

a median duration of 2.37 years, 259 patients (85.8%) achieved a
response (platelet count ≥50 × 109/L at least once in the absence of
rescue), while 133 (52%) of the responders achieved a continuous
response of a minimum of 25 weeks. Bleeding symptoms decreased by
41% in 1 year of treatment from baseline. 14% of patients withdrew
because of adverse events, which included hepatobiliary adverse events,
cataracts, deep vein thrombosis, cerebral infarction, headache, and
myelofibrosis. Treatment past one year did not increase rates of
thromboembolic or hepatobiliary adverse events. Overall EXTEND trial
demonstrated that long-term use of ELT was effective in maintaining a
reliable platelet count of 50 × 109/L or more while reducing bleeding in
most patients with ITP of more than 6 months. Adverse events were also
very infrequent [18].
In a randomized phase 3 trial (RAISE) by Gregory et al. that included
197 patients, 13 percent had adverse events of which the most common
were liver enzyme abnormalities and thromboembolic events [28]. They
found no significant differences in the development of malignancies or
cataracts in the ELT and placebo groups.
In a study by Brynes et al. 2 of 117 patients (1.7%) showed moderate
reticulin fibrosis of the bone marrow in patients receiving ELT who were
followed for up to 5.5 years [29]. However monitoring of bone marrow

Table 3
Response and Outcomes of ELT vs. standard (non-ELT) treatment in immune
thrombocytopenia and acquired idiopathic aplastic anemia.
Characteristic

ELT (n = 61)
IAA
ITP

Non-ELT (n = 60)
IAA
ITP

pvalue

Median Hb pretreatment (g/dl)
Median Hb posttreatment (g/dl)
Median WBC pretreatment (10E9/L)
Median WBC posttreatment (10E9/L)
Median Platelets pretreatment (10E9/L)
Median Platelets
post-treatment
(10E9/L)
Response
No
Yes

7.6

11.3

7.5

11.1

0.045

11.1

12.5

9.2

12.1

0.033

1.4

3.0

3.0

7.9

0.042

6.9

14.0

3.5

10.9

0.038

9

6

12

12

0.028

70

166

19

128

0.021

15
(46.9%)
17
(53.1%)

4
(13.8%)
25
(86.2%)

26
(86.7%)
4
(13.3%)

7
(23.3%)
23
(76.7%)

0.0006
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is not generally recommended nor part of guidelines by the American
Society of Hematology [30] The reason is, the absence of any evidence of
progression to myelofibrosis or serial bone marrow testing leading to
better outcomes. In addition, bone marrow biopsy is an uncomfortable
procedure for patients. Hence, patients in our center did not undergo
bone marrow biopsy post-treatment.
Other TPO-RAs include romiplostim and avatrombopag. Romiplos
tim is a once-weekly subcutaneous injection while ELT and ava
trombopag is a once-daily pill. Romiplostim has also shown a good
platelet response of around 80% in chronic ITP patients with a relatively
acceptable safety profile [31]. Avatrombopag was approved in 2018
however; there is very limited clinical experience with avatrombopag
compared with the other TPO-RAs.
The overall response rates are very promising in our population and
are comparable to previous experiences with eltrombopag in the Euro
pean and Chinese populations with a much better safety profile. The
resolution of cytopenias especially platelet counts within 6 weeks of
initiation of ELT in both AA and ITP makes them less prone to lifethreatening bleed.
Our study has several limitations. Being retrospective study causality
cannot be determined in terms of side effects, and so prospective trials
need to be designed in the future to assess better side effect profiles and
related additional factors. We also have a relatively smaller sample size
with a shorter follow-up. Further studies that monitor patients for a
longer duration would help us ascertain the durability of response and
toxicity profile.

[4]

[5]
[6]
[7]
[8]
[9]
[10]
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5. Conclusion
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This retrospective study found very promising results for ELT in both
ITP and AA. This makes it a reasonable choice for patients who can
afford the treatment and are compliant with long-term medications. ELT
showed complete response in 53.1% AA patients while approximately
90% platelet response in both AA and ITP patients. We also found a
significantly better response in AA and ITP patients when comparing
ELT with other standard treatment options. ELT is a reasonably effica
cious and safe drug. We suggest consideration of ELT in this subgroup of
patients to avoid early life-threatening infections and bleed.
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[3] A. Tichelli, H. Schrezenmeier, G. Socié, J. Marsh, A. Bacigalupo, U. Dührsen, et al.,
A randomized controlled study in patients with newly diagnosed severe aplastic

[29]

5

anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without GCSF: a study of the SAA working party of the European group for blood and marrow
transplantation, Blood. 117 (17) (2011) 4434–4441.
S.Y. Kao, W. Xu, J.M. Brandwein, J.H. Lipton, H.A. Messner, M.D. Minden, et al.,
Outcomes of older patients (>or = 60 years) with acquired aplastic anaemia
treated with immunosuppressive therapy, Br. J. Haematol. 143 (5) (2008)
738–743.
C. Neunert, N. Noroozi, G. Norman, G.R. Buchanan, J. Goy, I. Nazi, et al., Severe
bleeding events in adults and children with primary immune thrombocytopenia: a
systematic review, J. Thromb. Haemost 13 (3) (2015) 457–464.
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